Genmab A/S (GMAB) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Genmab A/S (GMAB) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 12.3% versus a loss of 1.1%. Over five years, PTCT leads with a +66.0% price change compared with -17.5% for GMAB. Genmab A/S is the larger company by market cap ($22.54 billion vs $5.28 billion), about 4.3 times the size, while PTC Therapeutics is growing revenue faster (+114.5% vs +19.2%).
On valuation, PTC Therapeutics trades at a lower forward P/E (23.6x vs 24.0x for Genmab A/S). PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus 25.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | PTCT |
|---|---|---|
| Share price | $36.65 | $63.23 |
| Market cap | $22.54B | $5.28B |
| 1-day change | -3.04% | -0.74% |
| YTD return | +18.99% | -16.76% |
| 1-year return | +12.29% | -1.06% |
| 5-year return | -17.51% | +66.00% |
| P/E ratio (TTM) | 29.80 | — |
| Forward P/E | 24.03 | 23.62 |
| EPS (TTM) | $1.23 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $1.73B |
| Revenue growth (YoY) | +19.19% | +114.51% |
| Net income (latest FY) | $963.00M | $682.64M |
| Gross margin | 93.60% | — |
| Operating margin | 28.63% | 50.09% |
| Net margin | 25.89% | 39.44% |
| 52-week high | $40.17 | $90.87 |
| 52-week low | $23.62 | $61.23 |
| Distance from 52-week high | -8.76% | -30.42% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +17.93% | +60.98% |
| Average volume | 2.78M | 1.15M |
| Shares outstanding | 614.90M | 83.46M |
| Employees | 3,119 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S is about 4.3 times larger than PTC Therapeutics by market value ($22.54B vs $5.28B).
- GMAB has outperformed PTCT by 13.3 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus 25.9 cents for Genmab A/S.
- PTC Therapeutics grew revenue faster in its latest fiscal year (+114.51% vs +19.19%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
GMAB vs PTCT FAQ
Which is bigger, Genmab A/S or PTC Therapeutics?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.54B compared with $5.28B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, GMAB or PTCT?
GMAB returned +12.29% over the past 12 months, compared with -1.06% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Genmab A/S and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.